Biodesix Inc. (BDSX)
Biodesix Statistics
Share Statistics
Biodesix has 145.98M shares outstanding. The number of shares has increased by 50.06% in one year.
Shares Outstanding | 145.98M |
Shares Change (YoY) | 50.06% |
Shares Change (QoQ) | 0.2% |
Owned by Institutions (%) | 40.09% |
Shares Floating | 74M |
Failed to Deliver (FTD) Shares | 14.8K |
FTD / Avg. Volume | 3.42% |
Short Selling Information
The latest short interest is 756.31K, so 0.52% of the outstanding shares have been sold short.
Short Interest | 756.31K |
Short % of Shares Out | 0.52% |
Short % of Float | 1.02% |
Short Ratio (days to cover) | 2.49 |
Valuation Ratios
The PE ratio is -4.62 and the forward PE ratio is -4.77. Biodesix's PEG ratio is 0.1.
PE Ratio | -4.62 |
Forward PE | -4.77 |
PS Ratio | 2.78 |
Forward PS | 0.6 |
PB Ratio | 9.5 |
P/FCF Ratio | -3.82 |
PEG Ratio | 0.1 |
Enterprise Valuation
Biodesix Inc. has an Enterprise Value (EV) of 185.39M.
EV / Earnings | -4.32 |
EV / Sales | 2.6 |
EV / EBITDA | -5.37 |
EV / EBIT | -5.37 |
EV / FCF | -3.57 |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 2.97.
Current Ratio | 2.76 |
Quick Ratio | 2.76 |
Debt / Equity | 2.97 |
Total Debt / Capitalization | 74.8 |
Cash Flow / Debt | -0.78 |
Interest Coverage | -4.18 |
Financial Efficiency
Return on equity (ROE) is -2.06% and return on capital (ROIC) is -41.64%.
Return on Equity (ROE) | -2.06% |
Return on Assets (ROA) | -0.44% |
Return on Capital (ROIC) | -41.64% |
Revenue Per Employee | $261,256.41 |
Profits Per Employee | $-157,256.41 |
Employee Count | 273 |
Asset Turnover | 0.73 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -48.95% in the last 52 weeks. The beta is 1.1, so Biodesix's price volatility has been higher than the market average.
Beta | 1.1 |
52-Week Price Change | -48.95% |
50-Day Moving Average | 0.91 |
200-Day Moving Average | 1.41 |
Relative Strength Index (RSI) | 36.09 |
Average Volume (20 Days) | 432.77K |
Income Statement
In the last 12 months, Biodesix had revenue of 71.32M and earned -42.93M in profits. Earnings per share was -0.33.
Revenue | 71.32M |
Gross Profit | 71.32M |
Operating Income | -34.5M |
Net Income | -42.93M |
EBITDA | -34.5M |
EBIT | -34.5M |
Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 26.25M in cash and 61.98M in debt, giving a net cash position of -35.73M.
Cash & Cash Equivalents | 26.25M |
Total Debt | 61.98M |
Net Cash | -35.73M |
Retained Earnings | -462.5M |
Total Assets | 97.24M |
Working Capital | 25.17M |
Cash Flow
In the last 12 months, operating cash flow was -48.65M and capital expenditures -3.23M, giving a free cash flow of -51.88M.
Operating Cash Flow | -48.65M |
Capital Expenditures | -3.23M |
Free Cash Flow | -51.88M |
FCF Per Share | -0.4 |
Margins
Gross margin is 100%, with operating and profit margins of -48.37% and -60.19%.
Gross Margin | 100% |
Operating Margin | -48.37% |
Pretax Margin | -60.19% |
Profit Margin | -60.19% |
EBITDA Margin | -48.37% |
EBIT Margin | -48.37% |
FCF Margin | -72.74% |
Dividends & Yields
BDSX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -45.21% |
FCF Yield | -48.9% |
Analyst Forecast
The average price target for BDSX is $3, which is 311% higher than the current price. The consensus rating is "Buy".
Price Target | $3 |
Price Target Difference | 311% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | -5.87 |
Piotroski F-Score | 3 |